Fact 4: Classification as Non-Small Cell Type
Pancoast tumors have a distinct identity, not only in their location and symptomatic presentation but also in their classification. They are predominantly classified as non-small cell lung cancers (NSCLC). To give context, NSCLCs account for about 85% of all lung cancers. Within this vast category, Pancoast tumors are often further classified as either adenocarcinomas or squamous cell carcinomas.
This classification isn’t just a nomenclature exercise; it bears weight on treatment and prognosis. NSCLCs behave differently compared to their counterpart, small cell lung cancers. They grow at a slower rate, but they also present a different set of challenges in terms of management.
The distinction between non-small cell types and small cell types is crucial for oncologists. Therapeutic strategies, prognostic outlooks, and patient counseling largely depend on this categorization. For patients, understanding their tumor’s classification offers insights into what they can expect regarding treatment options, side effects, and potential outcomes.
Furthermore, advances in genomic medicine have illuminated specific mutations associated with NSCLCs. This means that in some cases, targeted therapies can be utilized, which are designed to combat cancer cells bearing these mutations. (4)
